Lab
Efficiency

Implementing the American Society of Echocardiography Ultrasound Enhancing Agent Guidelines Into Your Facility's Policy Helps to Ensure the Appropriate Use of DEFINITY® for Improved Patient Care¹

Contrast Echo: See the Difference, Experience the Impact

Jonathan R. Lindner, MD, FACC, FASE, Lissa Sugeng, MD, MPH, FACC, FASE, Rajesh Janardhanan, MD, MCRP, FACC, FASE present the Lantheus 2015 ASE Science & Technology Theater Program.

DEFINITY® Delivers Clinical and Economic Value by Improving Diagnostic Accuracy, Lab Efficiency, and Workflow^2-4

Reduced resource utilization and per-patient expenses^2,3

Eliminated the need for redundant tests by 33%²

Associated with changes in use of vasoactive medications³

Reduced struggle time and may limit sonographer injury^4,5*

^{*Additional studies may be needed.}

Decreased
procedure time⁴

May increase
patient throughput^4,5

Peer-to-peer programs

Lantheus offers multiple peer-to-peer programs to increase echo quality, enhance lab efficiency, reduce cost, and improve patient care.

Ask your DEFINITY® representative about peer‑to‑peer programs

IMPROVE quality program

DEFINITY® is committed to delivering customer value through the IMPROVE quality program.

Understand your suboptimal echo rate
Demonstrate the impact of DEFINITY® through improved image quality and a reduction in overall costs

CONTACT YOUR DEFINITY® REPRESENTATIVE

Order DEFINITY® products

ORDER HERE

Explore the potential of DEFINITY® through our webinars

LEARN MORE

References:

Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography guidelines update. J Am Soc Echocardiogr. 2018;31(3):241-274.
Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
Main ML, Fu JW, Gundrum J, LaPointe NA, Gillam LD, Mulvagh SL. Impact of contrast echocardiography on outcomes in critically ill patients. Am J Cardiol. 2021;150:117-122.
Lester SJ, Askew JW, Hurst RT, et al. Contrast echocardiography: experience in a clinical echocardiography laboratory. J Am Soc Echocardiogr. 2006;19(7):919-923.
Castello R, Bella JN, Rovner A, Swan J, Smith J, Shaw L. Efficacy and time-efficiency of a “sonographer-driven” contrast echocardiography protocol in a high-volume echocardiography laboratory. Am Heart J. 2003;145(3):535-541.

DEFINITY® RT (Perflutren Lipid Microsphere) Injectable Suspension

INDICATIONS

Activated DEFINITY® and activated DEFINITY® RT (Perflutren Lipid Microsphere) Injectable Suspension are indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® and DEFINITY® RT to patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG).

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.

Assess all patients for the presence of any condition that precludes DEFINITY® and DEFINITY® RT administration [see Contraindications (4)].
Always have resuscitation equipment and trained personnel readily available.

In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren and PEG-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions and/or with pre-existing PEG hypersensitivity [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying conditions.

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® and DEFINITY® RT should be administered with caution.

Please see accompanying full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Customer Service 1.800.299.3431

BACK TO
TOP

LabEfficiency

Implementing the American Society of Echocardiography Ultrasound Enhancing Agent Guidelines Into Your Facility's Policy Helps to Ensure the Appropriate Use of DEFINITY® for Improved Patient Care1

DEFINITY® Delivers Clinical and Economic Value by Improving Diagnostic Accuracy, Lab Efficiency, and Workflow2-4

Peer-to-peer programs

IMPROVE quality program

Lab
Efficiency

Implementing the American Society of Echocardiography Ultrasound Enhancing Agent Guidelines Into Your Facility's Policy Helps to Ensure the Appropriate Use of DEFINITY® for Improved Patient Care¹

DEFINITY® Delivers Clinical and Economic Value by Improving Diagnostic Accuracy, Lab Efficiency, and Workflow^2-4